Skip to content

Study · Measured the body's own peptide · 2011

2 results

Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids.

Jensen JM, Ahrens K, Meingassner J, Scherer A, Bräutigam M, Stütz A, Schwarz T, Fölster-Holst R, Harder J, Gläser R, Proksch E

Experimental dermatology24 Jun 2011Cited by 37 (Europe PMC)

PMID21707760 (opens in a new tab)DOI10.1111/j.1600-0625.2011.01322.x (opens in a new tab)PepBankPUB-21707760
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialOther

    In atopic dermatitis skin, 3 weeks of topical betamethasone valerate or triamcinolone acetonide reduced cathelicidin LL‑37 protein expression to below the level in healthy control skin.

    In plain wordsIn people with atopic dermatitis, steroid creams lowered the skin's own LL‑37 below the level in healthy skin.

    Peptide
    LL-37
    Outcome
    DecreaseLL-37 protein expression in atopic dermatitis skin after corticosteroids
    Study

    n: not reported in source

    Comparator
    Healthy control skin
    Outcome group
    Immune response · Skin and wound

    Source sentences

    Summary
    BV and TA treatment in AD led to a significant reduction in AMP expression; protein expression of human beta-defensins (hBD)-2 and hBD-3, psoriasin, RNase 7 and cathelicidin LL-37 was below the level in skin of healthy controls.
    1 context sentence
    Summary · context
    We investigated the effects of topically applied corticosteroids betamethasone valerate (BV) and triamacinolone acetonide (TA) and those of the calcineurin inhibitor pimecrolimus for 3 weeks on AMP expression in AD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelNon-randomized trialOther

    In atopic dermatitis skin, 3 weeks of topical pimecrolimus reduced antimicrobial protein expression, but less than betamethasone valerate or triamcinolone acetonide; the abstract does not report LL‑37 separately for pimecrolimus.

    In plain wordsIn people with atopic dermatitis, pimecrolimus lowered the skin's own defence proteins less than steroid creams did. LL‑37 was not reported separately.

    Peptide
    LL-37
    Outcome
    DecreaseAntimicrobial protein expression in atopic dermatitis skin after pimecrolimus
    Study

    n: not reported in source

    Comparator
    Corticosteroids (BV, TA)
    Outcome group
    Immune response · Skin and wound

    Source sentences

    Summary
    After pimecrolimus treatment, AMP expression was also reduced but less compared to BV and TA; the expression levels of hBD-2, psoriasin and RNase 7 still remained above the control levels.
    1 context sentence
    Summary · context
    We investigated the effects of topically applied corticosteroids betamethasone valerate (BV) and triamacinolone acetonide (TA) and those of the calcineurin inhibitor pimecrolimus for 3 weeks on AMP expression in AD.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.